JP Morgan maintains AtriCure at Neutral, raises price target to $62 from $36

What happened

JP Morgan kept its Neutral rating on AtriCure and raised its price target to $62 from $36, a 72.2% increase. The new target implies 2.6% upside from AtriCure’s November 3 closing price of $60.41.

Confirmed

Global impact / market context

The higher target signals JP Morgan sees somewhat more potential value in AtriCure, but its Neutral rating indicates the firm did not change its overall stance. Because the target is only modestly above the cited closing price, the change alone suggests limited indicated upside.

Analyst inference

Recent analyst targets listed in the article range from $68 to $70, above JP Morgan’s $62 target. That difference shows JP Morgan’s valuation view is more cautious than the other cited recent notes, though ratings and targets are opinions, not guaranteed outcomes.

Confirmed

What to watch

1. Compare later AtriCure analyst ratings and targets with JP Morgan’s $62 figure to see whether other firms revise their views or the gap persists. Analyst inference
2. Watch for company results or guidance that could change expectations for sales, costs, or cash available and help explain any later analyst target revisions. Analyst inference
3. The article reports a November 3 closing price of $60.41 and says the $62 target implies 2.6% upside; it gives no later share-price data. Confirmed

Evidence

• Original source link unavailable